Work

An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Year: 2009

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v114.22.883.883

Authors: Andrew W. Roberts, John F Seymour, Jennifer R Brown, William G Wierda, Thomas J. Kipps, Dennis Carney, Hao Xiong, Yue Cui, Todd Busman, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse

Institutions: Walter and Eliza Hall Institute of Medical Research, Peter MacCallum Cancer Centre, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of California San Diego, Moores Cancer Center, Abbott (United States)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4243095254

FWCI: 2.114

Cites:

Cited by: 16

Related to: 10